PMID- 29141007
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 11
DP  - 2017
TI  - Escitalopram and NHT normalized stress-induced anhedonia and molecular 
      neuroadaptations in a mouse model of depression.
PG  - e0188043
LID - 10.1371/journal.pone.0188043 [doi]
LID - e0188043
AB  - Anhedonia is defined as a diminished ability to obtain pleasure from otherwise 
      positive stimuli. Anxiety and mood disorders have been previously associated with 
      dysregulation of the reward system, with anhedonia as a core element of major 
      depressive disorder (MDD). The aim of the present study was to investigate 
      whether stress-induced anhedonia could be prevented by treatments with 
      escitalopram or novel herbal treatment (NHT) in an animal model of depression. 
      Unpredictable chronic mild stress (UCMS) was administered for 4 weeks on ICR 
      outbred mice. Following stress exposure, animals were randomly assigned to 
      pharmacological treatment groups (i.e., saline, escitalopram or NHT). Treatments 
      were delivered for 3 weeks. Hedonic tone was examined via ethanol and sucrose 
      preferences. Biological indices pertinent to MDD and anhedonia were assessed: 
      namely, hippocampal brain-derived neurotrophic factor (BDNF) and striatal 
      dopamine receptor D2 (Drd2) mRNA expression levels. The results indicate that the 
      UCMS-induced reductions in ethanol or sucrose preferences were normalized by 
      escitalopram or NHT. This implies a resemblance between sucrose and ethanol in 
      their hedonic-eliciting property. On a neurobiological aspect, UCMS-induced 
      reduction in hippocampal BDNF levels was normalized by escitalopram or NHT, while 
      UCMS-induced reduction in striatal Drd2 mRNA levels was normalized solely by NHT. 
      The results accentuate the association of stress and anhedonia, and pinpoint a 
      distinct effect for NHT on striatal Drd2 expression.
FAU - Burstein, Or
AU  - Burstein O
AD  - School of Behavioral Science, The Academic College Tel-Aviv-Yaffo, Tel-Aviv, 
      Israel.
AD  - Department of Education and Psychology, The Open University, Raanana, Israel.
FAU - Franko, Motty
AU  - Franko M
AD  - School of Behavioral Science, The Academic College Tel-Aviv-Yaffo, Tel-Aviv, 
      Israel.
FAU - Gale, Eyal
AU  - Gale E
AD  - Department of Education and Psychology, The Open University, Raanana, Israel.
FAU - Handelsman, Assaf
AU  - Handelsman A
AD  - School of Psychological Sciences, Tel-Aviv University, Tel-Aviv, Israel.
AD  - The Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Barak, Segev
AU  - Barak S
AD  - School of Psychological Sciences, Tel-Aviv University, Tel-Aviv, Israel.
AD  - The Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Motsan, Shai
AU  - Motsan S
AD  - School of Behavioral Science, The Academic College Tel-Aviv-Yaffo, Tel-Aviv, 
      Israel.
FAU - Shamir, Alon
AU  - Shamir A
AD  - Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
AD  - Mazor Mental Health Center, Akko, Israel.
FAU - Toledano, Roni
AU  - Toledano R
AD  - School of Behavioral Science, The Academic College Tel-Aviv-Yaffo, Tel-Aviv, 
      Israel.
FAU - Simhon, Omri
AU  - Simhon O
AD  - School of Behavioral Science, The Academic College Tel-Aviv-Yaffo, Tel-Aviv, 
      Israel.
FAU - Hirshler, Yafit
AU  - Hirshler Y
AD  - Department of Education and Psychology, The Open University, Raanana, Israel.
FAU - Chen, Gang
AU  - Chen G
AD  - Center for Translational Systems Biology and Neuroscience, Nanjing University of 
      Chinese Medicine, Nanjing, China.
AD  - Key Laboratory of Integrative Biomedicine for Brain Diseases, Nanjing University 
      of Chinese Medicine, Nanjing, China.
FAU - Doron, Ravid
AU  - Doron R
AUID- ORCID: 0000-0002-6523-9886
AD  - School of Behavioral Science, The Academic College Tel-Aviv-Yaffo, Tel-Aviv, 
      Israel.
AD  - Department of Education and Psychology, The Open University, Raanana, Israel.
LA  - eng
PT  - Journal Article
DEP - 20171115
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Dopamine D2)
RN  - 0DHU5B8D6V (Citalopram)
SB  - IM
MH  - *Anhedonia
MH  - Animals
MH  - Antidepressive Agents, Second-Generation/pharmacology/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/genetics
MH  - Citalopram/pharmacology/*therapeutic use
MH  - Depression/*drug therapy/psychology
MH  - *Disease Models, Animal
MH  - *Herbal Medicine
MH  - Hippocampus/drug effects/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred ICR
MH  - RNA, Messenger/metabolism
MH  - Receptors, Dopamine D2/genetics
MH  - *Stress, Physiological
PMC - PMC5687745
COIS- Competing Interests: Dr. Ravid Doron has an approved patent relating the herbal 
      treatment for anxiety disorders (Patent No. 9,320,772, USA). This does not alter 
      our adherence to PLOS ONE policies on sharing data and materials. All other 
      authors declare no conflict of interest.
EDAT- 2017/11/16 06:00
MHDA- 2017/12/27 06:00
PMCR- 2017/11/15
CRDT- 2017/11/16 06:00
PHST- 2017/08/23 00:00 [received]
PHST- 2017/10/31 00:00 [accepted]
PHST- 2017/11/16 06:00 [entrez]
PHST- 2017/11/16 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
PHST- 2017/11/15 00:00 [pmc-release]
AID - PONE-D-17-31090 [pii]
AID - 10.1371/journal.pone.0188043 [doi]
PST - epublish
SO  - PLoS One. 2017 Nov 15;12(11):e0188043. doi: 10.1371/journal.pone.0188043. 
      eCollection 2017.